Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
12.12
-0.16 (-1.30%)
Mar 12, 2026, 4:00 PM EDT - Market closed
Benitec Biopharma Employees
Benitec Biopharma had 19 employees as of June 30, 2025. The number of employees increased by 3 or 18.75% compared to the previous year.
Employees
19
Change (1Y)
3
Growth (1Y)
18.75%
Revenue / Employee
n/a
Profits / Employee
-$2,321,474
Market Cap
415.17M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 19 | 3 | 18.75% |
| Jun 30, 2024 | 16 | -2 | -11.11% |
| Jun 30, 2023 | 18 | 0 | - |
| Jun 30, 2022 | 18 | 4 | 28.57% |
| Jun 30, 2021 | 14 | 0 | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| 4D Molecular Therapeutics | 227 |
| Sutro Biopharma | 178 |
| Lineage Cell Therapeutics | 77 |
| PepGen | 57 |
| PureTech Health | 56 |
| Shattuck Labs | 44 |
| Anavex Life Sciences | 34 |
| DiaMedica Therapeutics | 28 |
BNTC News
- 2 days ago - Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD) - GlobeNewsWire
- 5 weeks ago - Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade - Seeking Alpha
- 2 months ago - Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response - GlobeNewsWire
- 4 months ago - Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update - GlobeNewsWire
- 4 months ago - Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering - GlobeNewsWire
- 4 months ago - Benitec Biopharma Inc. Announces Proposed Public Offering - GlobeNewsWire
- 4 months ago - Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301 - GlobeNewsWire
- 4 months ago - Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy - GlobeNewsWire